Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gut microbiome dysbiosis is not associated with portal vein thrombosis in patients with end-stage liver disease: a cross-sectional study.
Aleksandrova RR, Nieuwenhuis LM, Karmi N, Zhang S, Swarte JC, Björk JR, Gacesa R, Blokzijl H, Connelly MA, Weersma RK, Lisman T, Festen EAM, de Meijer VE; TransplantLines Investigators. Aleksandrova RR, et al. Among authors: festen eam. J Thromb Haemost. 2025 Jan 9:S1538-7836(24)00791-8. doi: 10.1016/j.jtha.2024.12.036. Online ahead of print. J Thromb Haemost. 2025. PMID: 39798925 Free article.
Genome-wide meta-analysis associates donor-recipient non-HLA genetic mismatch with acute cellular rejection post-liver transplantation.
Nieuwenhuis LM, Li Y, Loza BL, Lambeck AJA, Hu S, Gacesa R, Voskuil MD, Hepkema BG, Jansen BH, Blokzijl H, Verkade HJ, van den Heuvel MC, Asrani S, Testa G, Klintmalm G, Trotter J, Olthoff KM, Shaked A, Keating BJ, Weersma RK, Festen EAM, de Meijer VE; TransplantLines Investigators. Nieuwenhuis LM, et al. Among authors: festen eam. Hepatol Commun. 2024 Dec 11;9(1):e0601. doi: 10.1097/HC9.0000000000000601. eCollection 2025 Jan 1. Hepatol Commun. 2024. PMID: 39670865 Free PMC article.
Long-Term Outcomes of Early Surgery vs Endoscopy First in Chronic Pancreatitis: Follow-Up Analysis of the ESCAPE Randomized Clinical Trial.
van Veldhuisen CL, Kempeneers MA, de Rijk FEM, Bouwense SA, Bruno MJ, Fockens P, Poley JW, Ali UA, Bollen TL, Busch OR, van Duijvendijk P, van Dullemen HM, van Eijck CH, Van Goor H, Hadithi M, Haveman JW, Keulemans Y, Nieuwenhuijs VB, Poen AC, Voermans RP, Tan AC, Thijs W, Verdonk RC, Witteman BJ, van Hooft JE, van Santvoort HC, Dijkgraaf MG, Besselink MG, Boermeester MA, Issa Y; Dutch Pancreatitis Study Group. van Veldhuisen CL, et al. JAMA Surg. 2024 Nov 20:e245182. doi: 10.1001/jamasurg.2024.5182. Online ahead of print. JAMA Surg. 2024. PMID: 39565607
Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease.
Prins FM, Hidding IJ, Klaassen MAY, Collij V, Schultheiss JPD, Uniken Venema WTC, Bangma A, Aardema JB, Jansen BH, Mares WGN, Witteman BJM, Festen EAM, Dijkstra G, Visschedijk MC, Fidder HH, Vich Vila A, Oldenburg B, Gacesa R, Weersma RK. Prins FM, et al. Among authors: festen eam. Gut Microbes. 2024 Jan-Dec;16(1):2391505. doi: 10.1080/19490976.2024.2391505. Epub 2024 Aug 21. Gut Microbes. 2024. PMID: 39167702 Free PMC article.
Genome-wide Studies Reveal Genetic Risk Factors for Hepatic Fat Content.
Li Y, van den Berg EH, Kurilshikov A, Zhernakova DV, Gacesa R, Hu S, Lopera-Maya EA, Zhernakova A; Lifelines Cohort Study; de Meijer VE, Sanna S, Dullaart RPF, Blokzijl H, Festen EAM, Fu J, Weersma RK. Li Y, et al. Among authors: festen eam. Genomics Proteomics Bioinformatics. 2024 Jul 3;22(2):qzae031. doi: 10.1093/gpbjnl/qzae031. Genomics Proteomics Bioinformatics. 2024. PMID: 39142818 Free article.
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
Bourgonje AR, Visschedijk MC, Festen EAM, Weersma RK, Dijkstra G. Bourgonje AR, et al. Among authors: festen eam. Lancet Gastroenterol Hepatol. 2024 Jul;9(7):590-591. doi: 10.1016/S2468-1253(24)00120-1. Lancet Gastroenterol Hepatol. 2024. PMID: 38870963 No abstract available.
Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease.
Gabriëls RY, van der Waaij AM, Linssen MD, Dobosz M, Volkmer P, Jalal S, Robinson D, Hermoso MA, Lub-de Hooge MN, Festen EAM, Kats-Ugurlu G, Dijkstra G, Nagengast WB. Gabriëls RY, et al. Among authors: festen eam. Gut. 2024 Aug 8;73(9):1454-1463. doi: 10.1136/gutjnl-2023-331696. Gut. 2024. PMID: 38580386 Free PMC article. Clinical Trial.
90 results